Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GBP2 CRISPR/Cas9 KO Plasmid (h): sc-402140
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GBP2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GBP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GBP2 Antibody (G-9): sc-271568
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GBP2 CRISPR/Cas9 KO Plasmid (h) | sc-402140 | 20 µg | $397.00 |
Overview
Guanylate binding protein 2 (GBP2) is an interferon-inducible large GTPase implicated in cell-intrinsic defense and inflammation-associated signaling. GBP2 localizes to cytosolic and membranous compartments where it participates in interferon-stimulated gene networks, regulation of pathogen-restrictive processes, and modulation of immune signaling pathways. Its activity links innate immune activation with downstream effects on cellular stress responses, cytokine-driven transcriptional programs, and remodeling of intracellular membranes. Dysregulated GBP2 expression and interferon pathway engagement have been associated with inflammatory states and immune-oncology phenotypes, making GBP2 a useful node for mechanistic studies of host response and immune regulation.
GBP2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GBP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GBP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GBP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GBP2 protein expression.
This CRISPR knockout system enables efficient generation of GBP2-deficient cell models for investigation of GBP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GBP2 exon(s) critical for GBP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GBP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GBP2 CRISPR/Cas9 KO Plasmid (h) and GBP2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GBP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GBP2 HDR Plasmid (h) and GBP2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GBP2 homology arms to support homology-directed repair at defined GBP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.